Literature DB >> 7595170

Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium.

L M Mulligan1, D J Marsh, B G Robinson, I Schuffenecker, J Zedenius, C J Lips, R F Gagel, S I Takai, W W Noll, M Fink.   

Abstract

The International RET Mutation Consortium was first convened as part of the Fifth International Workshop on Multiple Endocrine Neoplasia, Stockholm, Sweden, in an attempt to analyse the relationship of RET mutation and disease phenotype in the autosomal dominantly inherited multiple endocrine neoplasia type 2 (MEN 2) syndromes. Out of 361 families studied, 41% had MEN 2A, 17.7% MEN 2B, 6.4% FMTC and the remaining subjects were unclassified. RET mutations were detected in 87.3% of families overall. Over 93% of MEN 2B families had the RET 918 ATG-->ACG mutation, while the most frequent mutation detected in MEN 2A families was cysteine codon 634 (87% of all mutations).

Entities:  

Mesh:

Year:  1995        PMID: 7595170     DOI: 10.1111/j.1365-2796.1995.tb01208.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  51 in total

Review 1.  Multiple endocrine neoplasia type 2 and the practice of molecular medicine.

Authors:  C Eng
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

2.  Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation.

Authors:  Sina Jasim; Anita K Ying; Steven G Waguespack; Thereasa A Rich; Elizabeth G Grubbs; Camilo Jimenez; Mimi I Hu; Gilbert Cote; Mouhammed Amir Habra
Journal:  Thyroid       Date:  2010-12-27       Impact factor: 6.568

3.  Nine novel germline gene variants in the RET proto-oncogene identified in twelve unrelated cases.

Authors:  Syed A Ahmed; Karen Snow-Bailey; W Edward Highsmith; Weimin Sun; Raymond G Fenwick; Rong Mao
Journal:  J Mol Diagn       Date:  2005-05       Impact factor: 5.568

4.  Ret proto-oncogene mutations in apparently sporadic Turkish medullary thyroid carcinoma patients: Turkmen study.

Authors:  M F Erdogan; A Gürsoy; G Ozgen; M Cakir; F Bayram; R Ersoy; E Algün; B Cetinarslan; A Cömlekçi; P Kadioglu; M K Balci; I Yetkin; T Kabalak; G Erdogan
Journal:  J Endocrinol Invest       Date:  2005-10       Impact factor: 4.256

5.  Exon 5 of the RET proto-oncogene: a newly detected risk exon for familial medullary thyroid carcinoma, a novel germ-line mutation Gly321Arg.

Authors:  S Dvorakova; E Vaclavikova; J Duskova; P Vlcek; A Ryska; B Bendlova
Journal:  J Endocrinol Invest       Date:  2005-11       Impact factor: 4.256

Review 6.  Multiple endocrine neoplasia syndromes, children, Hirschsprung's disease and RET.

Authors:  S W Moore; M G Zaahl
Journal:  Pediatr Surg Int       Date:  2008-03-26       Impact factor: 1.827

7.  Ret-proto-oncogene analysis in medullary thyroid carcinoma.

Authors:  D A O'Keeffe; A D Hill; K Sheahan; F Ryan; D Barton; R J Fitzgerald; E W McDermott; N J O'Higgins
Journal:  Ir J Med Sci       Date:  1998 Oct-Dec       Impact factor: 1.568

Review 8.  The RET proto-oncogene: a challenge to our understanding of disease pathogenesis.

Authors:  T Kusafuka; P Puri
Journal:  Pediatr Surg Int       Date:  1997       Impact factor: 1.827

9.  Oncological implications of RET gene mutations in Hirschsprung's disease.

Authors:  R H Sijmons; R M Hofstra; F A Wijburg; T P Links; R P Zwierstra; A Vermey; D C Aronson; G Tan-Sindhunata; G J Brouwers-Smalbraak; S M Maas; C H Buys
Journal:  Gut       Date:  1998-10       Impact factor: 23.059

Review 10.  Update multiple endocrine neoplasia type 2.

Authors:  Friedhelm Raue; Karin Frank-Raue
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.